Why is is so hard to get trial patients?? Not t
Post# of 148110
Not to be negative but CD12 started over 7 months ago in mid-April: https://clinicaltrials.gov/ct2/show/NCT043472...amp;rank=2
Since then patients have been trickling in. I just don't understand. If 10s of thousands of Americans are getting covid (some with insurance, some without) why is it difficult to get a couple hundred people to get leronlimab for free?? Especially given the safety profile and lack of significant SOC.
60 MABs are now being tested from companies that don't have this struggle and timeline is a serious issue, its literally a treatment approval race.
Being reminded that we are still in an enrollement phase of the trial and seeing the patient number extend to 293 patients, I wonder how long it will take (as NP refuses goverment support) before 293 patients are in the trial.
Seems like with the current pandemic conditions, safety profile, CD-10 data, Montifiore experiences, theraputic conferences, and lack of substantial SOC - as well as the 10s of thousands of patients getting covid constantly it would take weeks, not months to get 300 people to agree to take leronimab for free.
What am I missing? I'd love to get this question off my head. Please help me understand the reason it takes 7+ months and counting given all these conditions. What a shame for loss of lives around the world!!
Since this is a "negative" question (but a valid one) but I am so AMAZED at the MOA and efficacy of LERONLIMAB TREATING THE PROBLEM ( viral replication and cytokine storm that causes auto immune response) AND NOT THE SYMPTOMS , I wanted to share some awesome PR for leronlimab that posted by Calstang earlier today in case anybody missed it: https://www.zerohedge.com/news/2020-10-20/unr...es-hanging
I don't want the focus of today to be diverted. This is just a side question that has been on my head for months and also wondering how long people think it will take to get to 293 patients.
- Thanks in advance for sharing your insights, I'm really stumped over this.